AB SCIENCE SA (AB.PA)
FR0010557264 - Common Stock
We assign a fundamental rating of 1 out of 10 to AB. AB was compared to 47 industry peers in the Pharmaceuticals industry. AB has a bad profitability rating. Also its financial health evaluation is rather negative. AB is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
AB had negative earnings in the past year.
In the past year AB has reported a negative cash flow from operations.
In the past 5 years AB always reported negative net income.
In the past 5 years AB always reported negative operating cash flow.
1.2 Ratios
AB has a Return On Assets of -47.00%. This is amonst the worse of the industry: AB underperforms 83.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-57.37%
ROA(5y)-69.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 60.52%, AB is not doing good in the industry: 65.12% of the companies in the same industry are doing better.
AB's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for AB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.15%
GM growth 5Y-6.66%
2. Health
2.1 Basic Checks
AB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AB has more shares outstanding
AB has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, AB has an improved debt to assets ratio.
2.2 Solvency
AB has an Altman-Z score of -16.24. This is a bad value and indicates that AB is not financially healthy and even has some risk of bankruptcy.
AB has a worse Altman-Z score (-16.24) than 93.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.24 |
ROIC/WACCN/A
WACC6.53%
2.3 Liquidity
AB has a Current Ratio of 1.04. This is a normal value and indicates that AB is financially healthy and should not expect problems in meeting its short term obligations.
AB has a worse Current ratio (1.04) than 76.74% of its industry peers.
AB has a Quick Ratio of 1.02. This is a normal value and indicates that AB is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.02, AB is in line with its industry, outperforming 58.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.04 | ||
| Quick Ratio | 1.02 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 13.71% over the past year.
Looking at the last year, AB shows a small growth in Revenue. The Revenue has grown by 1.25% in the last year.
AB shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -10.63% yearly.
EPS 1Y (TTM)13.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.85%
Revenue 1Y (TTM)1.25%
Revenue growth 3Y-15.06%
Revenue growth 5Y-10.63%
Sales Q2Q%58.66%
3.2 Future
Based on estimates for the next years, AB will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.36% on average per year.
Based on estimates for the next years, AB will show a quite strong growth in Revenue. The Revenue will grow by 14.50% on average per year.
EPS Next Y38.24%
EPS Next 2Y18.59%
EPS Next 3Y14.36%
EPS Next 5YN/A
Revenue Next Year0%
Revenue Next 2Y17.78%
Revenue Next 3Y14.5%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
AB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AB's earnings are expected to grow with 14.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.59%
EPS Next 3Y14.36%
5. Dividend
5.1 Amount
No dividends for AB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AB SCIENCE SA
EPA:AB (9/16/2024, 7:00:00 PM)
1.032
+0.01 (+1.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap54.05M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.52% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.04 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)13.71%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y38.24%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1.25%
Revenue growth 3Y-15.06%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y